Salicylic acid and derivatives
Salicylic acid and derivatives has been studied in 2 papers since 2025: 2 observational studies in people; 1 in the past year. The newest paper, Jan 27, 2026: “Risk insights for clinical medication: a Mendelian randomization study of 23 drugs and lung cancer”.
2 papers study it2 findingsUpdated
See all 2 papers on salicylic acid and derivatives
At a glance
The findings reach people, from one lab or study. 2 independent labs in 1 country.
“salicylic acid and derivatives (OR = 0.779; 95% CI, 0.676-0.898; P = 5 × 10−4, P-adjusted = 0.0125) significantly reduced lung cancer risk”
None of its findings points the other way.
- 2 independent labs in 1 country
- Funders: National Natural Science Foundation of China and 2 more
- Humans2
What is salicylic acid and derivatives linked with?
2Studies link salicylic acid and derivatives with 2 measures: lung cancer and dementia with Lewy bodies.
Lung cancer
downin humans1OR 0.779
1 study
Lung cancer
downin humans1OR 0.779
Salicylic acid and derivatives are linked with a lower risk of lung cancer in humans (OR = 0.779; 95% CI, 0.676-0.898).
“salicylic acid and derivatives (OR = 0.779; 95% CI, 0.676-0.898; P = 5 × 10−4, P-adjusted = 0.0125) significantly reduced lung cancer risk”
Humans
Risk insights for clinical medication: a Mendelian randomization study of 23 drugs and lung cancer
Naunyn-Schmiedeberg's archives of pharmacology
Dementia with Lewy bodies
upin humans1OR 2.77
1 study
Dementia with Lewy bodies
upin humans1OR 2.77
Salicylic acid and derivatives are linked with a higher risk of dementia with Lewy bodies in humans (two-sample Mendelian randomization, inverse-variance weighted estimate) (OR 2.77, 95% CI 1.44-5.32, p = 0.002).
“salicylic acid and derivatives (OR = 2.77, 95% CI = 1.44-5.32, p = 0.002) are a strong risk factor for dementia with Lewy bodies (DLB)”
Humanstwo-sample Mendelian randomization, inverse-variance weighted estimate
Brain and behavior